-
1
-
-
70349443284
-
When mutants gain new powers: news from the mutant p53 field
-
Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009, 9:701-713.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 701-713
-
-
Brosh, R.1
Rotter, V.2
-
2
-
-
34047207337
-
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes
-
10.1038/sj.onc.1210302, 17401424
-
Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007, 26:2157-2165. 10.1038/sj.onc.1210302, 17401424.
-
(2007)
Oncogene
, vol.26
, pp. 2157-2165
-
-
Petitjean, A.1
Achatz, M.I.2
Borresen-Dale, A.L.3
Hainaut, P.4
Olivier, M.5
-
3
-
-
24344448786
-
P53 isoforms can regulate p53 transcriptional activity
-
10.1101/gad.1339905, 1221884, 16131611
-
Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005, 19:2122-2137. 10.1101/gad.1339905, 1221884, 16131611.
-
(2005)
Genes Dev
, vol.19
, pp. 2122-2137
-
-
Bourdon, J.C.1
Fernandes, K.2
Murray-Zmijewski, F.3
Liu, G.4
Diot, A.5
Xirodimas, D.P.6
Saville, M.K.7
Lane, D.P.8
-
4
-
-
36849069347
-
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
-
10.1200/JCO.2007.14.2364, 17954709
-
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312. 10.1200/JCO.2007.14.2364, 17954709.
-
(2007)
J Clin Oncol
, vol.25
, pp. 5287-5312
-
-
Harris, L.1
Fritsche, H.2
Mennel, R.3
Norton, L.4
Ravdin, P.5
Taube, S.6
Somerfield, M.R.7
Hayes, D.F.8
Bast, R.C.9
-
5
-
-
0037221767
-
TP53 and breast cancer
-
10.1002/humu.10174, 12619115
-
Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003, 21:292-300. 10.1002/humu.10174, 12619115.
-
(2003)
Hum Mutat
, vol.21
, pp. 292-300
-
-
Borresen-Dale, A.L.1
-
6
-
-
80052650919
-
TP53 status and response to treatment in breast cancers
-
3114547, 21760703
-
Varna M, Bousquet G, Plassa LF, Bertheau P, Janin A. TP53 status and response to treatment in breast cancers. J Biomed Biotechnol 2011, 2011:284584. 3114547, 21760703.
-
(2011)
J Biomed Biotechnol
, vol.2011
, pp. 284584
-
-
Varna, M.1
Bousquet, G.2
Plassa, L.F.3
Bertheau, P.4
Janin, A.5
-
7
-
-
79961000358
-
P53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905)
-
10.1158/1078-0432.CCR-11-0484, 3149770, 21693655
-
Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res 2011, 17:5170-5178. 10.1158/1078-0432.CCR-11-0484, 3149770, 21693655.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5170-5178
-
-
Lara, J.F.1
Thor, A.D.2
Dressler, L.G.3
Broadwater, G.4
Bleiweiss, I.J.5
Edgerton, S.6
Cowan, D.7
Goldstein, L.J.8
Martino, S.9
Ingle, J.N.10
Henderson, I.C.11
Norton, L.12
Winer, E.P.13
Hudis, C.A.14
Ellis, M.J.15
Berry, D.A.16
Hayes, D.F.17
-
8
-
-
84861530773
-
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane based adjuvant therapy: results from the BIG 02-98 phase III trial
-
10.1186/bcr3179, 3446332, 22551440
-
Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, De Azambuja E, Hainaut P, Dell'orto P, Larsimont D, Francis PA, Crown J, Piccart-Gebhart M, Viale G, Di Leo A, Olivier M. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 2012, 14:R70. 10.1186/bcr3179, 3446332, 22551440.
-
(2012)
Breast Cancer Res
, vol.14
-
-
Fernandez-Cuesta, L.1
Oakman, C.2
Falagan-Lotsch, P.3
Smoth, K.S.4
Quinaux, E.5
Buyse, M.6
Dolci, M.S.7
De Azambuja, E.8
Hainaut, P.9
Dell'orto, P.10
Larsimont, D.11
Francis, P.A.12
Crown, J.13
Piccart-Gebhart, M.14
Viale, G.15
Di Leo, A.16
Olivier, M.17
-
9
-
-
79957527931
-
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
-
10.1016/S1470-2045(11)70094-8, 21570352
-
Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, Andre S, Litiere S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011, 12:527-539. 10.1016/S1470-2045(11)70094-8, 21570352.
-
(2011)
Lancet Oncol
, vol.12
, pp. 527-539
-
-
Bonnefoi, H.1
Piccart, M.2
Bogaerts, J.3
Mauriac, L.4
Fumoleau, P.5
Brain, E.6
Petit, T.7
Rouanet, P.8
Jassem, J.9
Blot, E.10
Zaman, K.11
Cufer, T.12
Lortholary, A.13
Lidbrink, E.14
Andre, S.15
Litiere, S.16
Lago, L.D.17
Becette, V.18
Cameron, D.A.19
Bergh, J.20
Iggo, R.21
more..
-
10
-
-
0029043805
-
A simple p53 functional assay for screening cell lines, blood, and tumors
-
10.1073/pnas.92.9.3963, 42082, 7732013
-
Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhattar J. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995, 92:3963-3967. 10.1073/pnas.92.9.3963, 42082, 7732013.
-
(1995)
Proc Natl Acad Sci USA
, vol.92
, pp. 3963-3967
-
-
Flaman, J.M.1
Frebourg, T.2
Moreau, V.3
Charbonnier, F.4
Martin, C.5
Chappuis, P.6
Sappino, A.P.7
Limacher, I.M.8
Bron, L.9
Benhattar, J.10
-
11
-
-
0031022938
-
Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract
-
10.1038/sj.onc.1200812, 9010218
-
Waridel F, Estreicher A, Bron L, Flaman JM, Fontolliet C, Monnier P, Frebourg T, Iggo R. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene 1997, 14:163-169. 10.1038/sj.onc.1200812, 9010218.
-
(1997)
Oncogene
, vol.14
, pp. 163-169
-
-
Waridel, F.1
Estreicher, A.2
Bron, L.3
Flaman, J.M.4
Fontolliet, C.5
Monnier, P.6
Frebourg, T.7
Iggo, R.8
-
12
-
-
79954612499
-
Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers
-
10.1158/1078-0432.CCR-10-1045, 21248301
-
Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans F, Uzan S, Andre F, de TH, Pusztai L. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin Cancer Res 2011, 17:2591-1601. 10.1158/1078-0432.CCR-10-1045, 21248301.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 2591-11601
-
-
Coutant, C.1
Rouzier, R.2
Qi, Y.3
Lehmann-Che, J.4
Bianchini, G.5
Iwamoto, T.6
Hortobagyi, G.N.7
Symmans, F.8
Uzan, S.9
Andre, F.10
de, T.H.11
Pusztai, L.12
-
13
-
-
26444546442
-
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival
-
10.1073/pnas.0506230102, 1197273, 16141321
-
Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102:13550-13555. 10.1073/pnas.0506230102, 1197273, 16141321.
-
(2005)
Proc Natl Acad Sci USA
, vol.102
, pp. 13550-13555
-
-
Miller, L.D.1
Smeds, J.2
George, J.3
Vega, V.B.4
Vergara, L.5
Ploner, A.6
Pawitan, Y.7
Hall, P.8
Klaar, S.9
Liu, E.T.10
Bergh, J.11
-
14
-
-
33846576225
-
Gene expression patterns associated with p53 status in breast cancer
-
10.1186/1471-2407-6-276, 1764759, 17150101
-
Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, Barbier CS, Perou CM. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006, 6:276. 10.1186/1471-2407-6-276, 1764759, 17150101.
-
(2006)
BMC Cancer
, vol.6
, pp. 276
-
-
Troester, M.A.1
Herschkowitz, J.I.2
Oh, D.S.3
He, X.4
Hoadley, K.A.5
Barbier, C.S.6
Perou, C.M.7
-
15
-
-
0035225608
-
Prognostic value of p53 protein expression in breast cancer; an immunohistochemical analysis of frozen sections in 514 Japanese women
-
10.1007/BF02967508, 11668240
-
Tsutsui S, Ohno S, Murakam S, Hachitanda Y, Oda S. Prognostic value of p53 protein expression in breast cancer; an immunohistochemical analysis of frozen sections in 514 Japanese women. Breast Cancer 2001, 8:194-201. 10.1007/BF02967508, 11668240.
-
(2001)
Breast Cancer
, vol.8
, pp. 194-201
-
-
Tsutsui, S.1
Ohno, S.2
Murakam, S.3
Hachitanda, Y.4
Oda, S.5
-
16
-
-
0028173703
-
P53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment
-
10.1002/1097-0142(19940415)73:8<2147::AID-CNCR2820730820>3.0.CO;2-5, 8156519
-
Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, Parl FF. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer 1994, 73:2147-2156. 10.1002/1097-0142(19940415)73:8<2147::AID-CNCR2820730820>3.0.CO;2-5, 8156519.
-
(1994)
Cancer
, vol.73
, pp. 2147-2156
-
-
Caleffi, M.1
Teague, M.W.2
Jensen, R.A.3
Vnencak-Jones, C.L.4
Dupont, W.D.5
Parl, F.F.6
-
17
-
-
33644772215
-
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer
-
10.1158/1078-0432.CCR-05-1029, 16489069
-
Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Borresen-Dale AL. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006, 12:1157-1167. 10.1158/1078-0432.CCR-05-1029, 16489069.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 1157-1167
-
-
Olivier, M.1
Langerod, A.2
Carrieri, P.3
Bergh, J.4
Klaar, S.5
Eyfjord, J.6
Theillet, C.7
Rodriguez, C.8
Lidereau, R.9
Bieche, I.10
Varley, J.11
Bignon, Y.12
Uhrhammer, N.13
Winqvist, R.14
Jukkola-Vuorinen, A.15
Niederacher, D.16
Kato, S.17
Ishioka, C.18
Hainaut, P.19
Borresen-Dale, A.L.20
more..
-
18
-
-
34250760957
-
TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer
-
10.1186/bcr1675, 1929092, 17504517
-
Langerod A, Zhao H, Borgan O, Nesland JM, Bukholm IR, Ikdahl T, Karesen R, Borresen-Dale AL, Jeffrey SS. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007, 9:R30. 10.1186/bcr1675, 1929092, 17504517.
-
(2007)
Breast Cancer Res
, vol.9
-
-
Langerod, A.1
Zhao, H.2
Borgan, O.3
Nesland, J.M.4
Bukholm, I.R.5
Ikdahl, T.6
Karesen, R.7
Borresen-Dale, A.L.8
Jeffrey, S.S.9
-
19
-
-
0035845511
-
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
-
10.1073/pnas.191367098, 58566, 11553815
-
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, pp. 10869-10874
-
-
Sorlie, T.1
Perou, C.M.2
Tibshirani, R.3
Aas, T.4
Geisler, S.5
Johnsen, H.6
Hastie, T.7
Eisen, M.B.8
van de Rijn, M.9
Jeffrey, S.S.10
Thorsen, T.11
Quist, H.12
Matese, J.C.13
Brown, P.O.14
Botstein, D.15
Eystein Lonning, P.16
Borresen-Dale, A.L.17
-
20
-
-
78651100119
-
Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures
-
10.1073/pnas.1017001108, 3012457, 21149740
-
Mizuno H, Spike BT, Wahl GM, Levine AJ. Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci USA 2010, 107:22745-22750. 10.1073/pnas.1017001108, 3012457, 21149740.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 22745-22750
-
-
Mizuno, H.1
Spike, B.T.2
Wahl, G.M.3
Levine, A.J.4
-
21
-
-
0027394794
-
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer
-
10.1093/jnci/85.3.200, 8423624
-
Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993, 85:200-206. 10.1093/jnci/85.3.200, 8423624.
-
(1993)
J Natl Cancer Inst
, vol.85
, pp. 200-206
-
-
Allred, D.C.1
Clark, G.M.2
Elledge, R.3
Fuqua, S.A.4
Brown, R.W.5
Chamness, G.C.6
Osborne, C.K.7
McGuire, W.L.8
-
22
-
-
0028844391
-
Hormonal regulation of the p53 tumor suppressor protein in T47D human breast carcinoma cell line
-
10.1074/jbc.270.48.28507, 7499360
-
Hurd C, Khattree N, Alban P, Nag K, Jhanwar SC, Dinda S, Moudgil VK. Hormonal regulation of the p53 tumor suppressor protein in T47D human breast carcinoma cell line. J Biol Chem 1995, 270:28507-28510. 10.1074/jbc.270.48.28507, 7499360.
-
(1995)
J Biol Chem
, vol.270
, pp. 28507-28510
-
-
Hurd, C.1
Khattree, N.2
Alban, P.3
Nag, K.4
Jhanwar, S.C.5
Dinda, S.6
Moudgil, V.K.7
-
23
-
-
0034657403
-
Estradiol induces functional inactivation of p53 by intracellular redistribution
-
Molinari AM, Bontempo P, Schiavone EM, Tortora V, Verdicchio MA, Napolitano M, Nola E, Moncharmont B, Medici N, Nigro V, Armetta I, Abbondanza C, Puca GA. Estradiol induces functional inactivation of p53 by intracellular redistribution. Cancer Res 2000, 60:2594-2597.
-
(2000)
Cancer Res
, vol.60
, pp. 2594-2597
-
-
Molinari, A.M.1
Bontempo, P.2
Schiavone, E.M.3
Tortora, V.4
Verdicchio, M.A.5
Napolitano, M.6
Nola, E.7
Moncharmont, B.8
Medici, N.9
Nigro, V.10
Armetta, I.11
Abbondanza, C.12
Puca, G.A.13
-
24
-
-
65949102326
-
Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells
-
10.1158/0008-5472.CAN-08-3628, 3079369, 19351845
-
Shirley SH, Rundhaug JE, Tian J, Cullinan-Ammann N, Lambertz I, Conti CJ, Fuchs-Young R. Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res 2009, 69:3405-3414. 10.1158/0008-5472.CAN-08-3628, 3079369, 19351845.
-
(2009)
Cancer Res
, vol.69
, pp. 3405-3414
-
-
Shirley, S.H.1
Rundhaug, J.E.2
Tian, J.3
Cullinan-Ammann, N.4
Lambertz, I.5
Conti, C.J.6
Fuchs-Young, R.7
-
25
-
-
0141988721
-
P53 function is required for hormone-mediated protection of mouse mammary tumorigenesis
-
Medina D, Kittrell FS. p53 function is required for hormone-mediated protection of mouse mammary tumorigenesis. Cancer Res 2003, 63:6140-6143.
-
(2003)
Cancer Res
, vol.63
, pp. 6140-6143
-
-
Medina, D.1
Kittrell, F.S.2
-
26
-
-
0035940463
-
P53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis
-
10.1073/pnas.221459098, 60062, 11606748
-
Sivaraman L, Conneely OM, Medina D, O'Malley BW. p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. Proc Natl Acad Sci USA 2001, 98:12379-12384. 10.1073/pnas.221459098, 60062, 11606748.
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, pp. 12379-12384
-
-
Sivaraman, L.1
Conneely, O.M.2
Medina, D.3
O'Malley, B.W.4
-
27
-
-
20244370996
-
The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways
-
10.1006/bbrc.1997.7522, 9344880
-
Yu CL, Driggers P, Barrera-Hernandez G, Nunez SB, Segars JH, Cheng S. The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. Biochem Biophys Res Commun 1997, 239:617-620. 10.1006/bbrc.1997.7522, 9344880.
-
(1997)
Biochem Biophys Res Commun
, vol.239
, pp. 617-620
-
-
Yu, C.L.1
Driggers, P.2
Barrera-Hernandez, G.3
Nunez, S.B.4
Segars, J.H.5
Cheng, S.6
-
28
-
-
0034127791
-
Estrogen receptor protects p53 from deactivation by human double minute-2
-
Liu G, Schwartz JA, Brooks SC. Estrogen receptor protects p53 from deactivation by human double minute-2. Cancer Res 2000, 60:1810-1814.
-
(2000)
Cancer Res
, vol.60
, pp. 1810-1814
-
-
Liu, G.1
Schwartz, J.A.2
Brooks, S.C.3
-
29
-
-
33744532403
-
Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function
-
10.1074/jbc.C600001200, 16469747
-
Liu W, Konduri SD, Bansal S, Nayak BK, Rajasekaran SA, Karuppayil SM, Rajasekaran AK, Das GM. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 2006, 281:9837-9840. 10.1074/jbc.C600001200, 16469747.
-
(2006)
J Biol Chem
, vol.281
, pp. 9837-9840
-
-
Liu, W.1
Konduri, S.D.2
Bansal, S.3
Nayak, B.K.4
Rajasekaran, S.A.5
Karuppayil, S.M.6
Rajasekaran, A.K.7
Das, G.M.8
-
30
-
-
76549137189
-
Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences
-
Menendez D, Inga A, Resnick MA. Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences. Proc Natl Acad Sci USA 107:1500-1505.
-
Proc Natl Acad Sci USA
, vol.107
, pp. 1500-1505
-
-
Menendez, D.1
Inga, A.2
Resnick, M.A.3
-
31
-
-
0015550689
-
Estrogen receptors in human breast cancer
-
10.1172/JCI107175, 302228, 4345203
-
McGuire WL. Estrogen receptors in human breast cancer. J Clin Invest 1973, 52:73-77. 10.1172/JCI107175, 302228, 4345203.
-
(1973)
J Clin Invest
, vol.52
, pp. 73-77
-
-
McGuire, W.L.1
-
32
-
-
0025094132
-
Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer
-
Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 1990, 50:7057-7061.
-
(1990)
Cancer Res
, vol.50
, pp. 7057-7061
-
-
Reiner, A.1
Neumeister, B.2
Spona, J.3
Reiner, G.4
Schemper, M.5
Jakesz, R.6
-
33
-
-
0032896905
-
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
-
Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17:1474-1481.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1474-1481
-
-
Harvey, J.M.1
Clark, G.M.2
Osborne, C.K.3
Allred, D.C.4
-
34
-
-
0142216643
-
Prognosis in node-negative primary breast cancer: a neural network analysis of risk profiles using routinely assessed factors
-
10.1093/annonc/mdg422, 14504047
-
Biganzoli E, Boracchi P, Coradini D, Grazia Daidone M, Marubini E. Prognosis in node-negative primary breast cancer: a neural network analysis of risk profiles using routinely assessed factors. Ann Oncol 2003, 14:1484-1493. 10.1093/annonc/mdg422, 14504047.
-
(2003)
Ann Oncol
, vol.14
, pp. 1484-1493
-
-
Biganzoli, E.1
Boracchi, P.2
Coradini, D.3
Grazia Daidone, M.4
Marubini, E.5
-
35
-
-
0034688187
-
Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers
-
10.1002/(SICI)1097-0215(20000120)89:1<92::AID-IJC15>3.0.CO;2-8, 10719737
-
Takahashi M, Tonoki H, Tada M, Kashiwazaki H, Furuuchi K, Hamada J, Fujioka Y, Sato Y, Takahashi H, Todo S, Sakuragi N, Moriuchi T. Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int J Cancer 2000, 89:92-99. 10.1002/(SICI)1097-0215(20000120)89:1<92::AID-IJC15>3.0.CO;2-8, 10719737.
-
(2000)
Int J Cancer
, vol.89
, pp. 92-99
-
-
Takahashi, M.1
Tonoki, H.2
Tada, M.3
Kashiwazaki, H.4
Furuuchi, K.5
Hamada, J.6
Fujioka, Y.7
Sato, Y.8
Takahashi, H.9
Todo, S.10
Sakuragi, N.11
Moriuchi, T.12
-
36
-
-
80053151094
-
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer
-
10.1093/annonc/mdq735, 3179412, 21325445
-
Karlsson P, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Collins J, Murray E, Zaman K, Colleoni M, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A. Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Ann Oncol 2011, 22:2216-2226. 10.1093/annonc/mdq735, 3179412, 21325445.
-
(2011)
Ann Oncol
, vol.22
, pp. 2216-2226
-
-
Karlsson, P.1
Sun, Z.2
Braun, D.3
Price, K.N.4
Castiglione-Gertsch, M.5
Rabaglio, M.6
Gelber, R.D.7
Crivellari, D.8
Collins, J.9
Murray, E.10
Zaman, K.11
Colleoni, M.12
Gusterson, B.A.13
Viale, G.14
Regan, M.M.15
Coates, A.S.16
Goldhirsch, A.17
-
37
-
-
79961009392
-
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX
-
10.1093/annonc/mdq754, 3202167, 21282282
-
Aebi S, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Lindtner J, Snyder R, Karlsson P, Simoncini E, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol 2011, 22:1981-1987. 10.1093/annonc/mdq754, 3202167, 21282282.
-
(2011)
Ann Oncol
, vol.22
, pp. 1981-1987
-
-
Aebi, S.1
Sun, Z.2
Braun, D.3
Price, K.N.4
Castiglione-Gertsch, M.5
Rabaglio, M.6
Gelber, R.D.7
Crivellari, D.8
Lindtner, J.9
Snyder, R.10
Karlsson, P.11
Simoncini, E.12
Gusterson, B.A.13
Viale, G.14
Regan, M.M.15
Coates, A.S.16
Goldhirsch, A.17
-
38
-
-
33750576185
-
Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays
-
For the International Breast Cancer Study G
-
Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurkula M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B, . For the International Breast Cancer Study G Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays. J Natl Cancer Inst Cancer Spectrum 2006, 98:1571-1581. For the International Breast Cancer Study G.
-
(2006)
J Natl Cancer Inst Cancer Spectrum
, vol.98
, pp. 1571-1581
-
-
Regan, M.M.1
Viale, G.2
Mastropasqua, M.G.3
Maiorano, E.4
Golouh, R.5
Carbone, A.6
Brown, B.7
Suurkula, M.8
Langman, G.9
Mazzucchelli, L.10
Braye, S.11
Grigolato, P.12
Gelber, R.D.13
Castiglione-Gertsch, M.14
Price, K.N.15
Coates, A.S.16
Goldhirsch, A.17
Gusterson, B.18
-
39
-
-
41149114592
-
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group
-
10.1200/JCO.2007.10.6393, 18349391
-
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovacs A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. J Clin Oncol 2008, 26:1404-1410. 10.1200/JCO.2007.10.6393, 18349391.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1404-1410
-
-
Viale, G.1
Regan, M.M.2
Maiorano, E.3
Mastropasqua, M.G.4
Golouh, R.5
Perin, T.6
Brown, R.W.7
Kovacs, A.8
Pillay, K.9
Ohlschlegel, C.10
Braye, S.11
Grigolato, P.12
Rusca, T.13
Gelber, R.D.14
Castiglione-Gertsch, M.15
Price, K.N.16
Goldhirsch, A.17
Gusterson, B.A.18
Coates, A.S.19
-
40
-
-
77951926837
-
Adverse prognostic value of vessel invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
-
2813305, 19633051, International Breast Cancer Study G
-
Viale G, Giobbie-Hurder A, Gusterson B, Maiorano E, Mastropasqua MG, Sonzogni A, Colleoni M, Castiglione-Gertsch M, Price KN, Gelber RD, Goldhirsch A, Coates AS, . International Breast Cancer Study G Adverse prognostic value of vessel invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Ann Oncol 2009, 21:245-254. 2813305, 19633051, International Breast Cancer Study G.
-
(2009)
Ann Oncol
, vol.21
, pp. 245-254
-
-
Viale, G.1
Giobbie-Hurder, A.2
Gusterson, B.3
Maiorano, E.4
Mastropasqua, M.G.5
Sonzogni, A.6
Colleoni, M.7
Castiglione-Gertsch, M.8
Price, K.N.9
Gelber, R.D.10
Goldhirsch, A.11
Coates, A.S.12
-
41
-
-
84863116462
-
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry
-
10.1200/JCO.2011.36.2574, 22291085
-
Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 2012, 30:729-734. 10.1200/JCO.2011.36.2574, 22291085.
-
(2012)
J Clin Oncol
, vol.30
, pp. 729-734
-
-
Iwamoto, T.1
Booser, D.2
Valero, V.3
Murray, J.L.4
Koenig, K.5
Esteva, F.J.6
Ueno, N.T.7
Zhang, J.8
Shi, W.9
Qi, Y.10
Matsuoka, J.11
Yang, E.J.12
Hortobagyi, G.N.13
Hatzis, C.14
Symmans, W.F.15
Pusztai, L.16
-
42
-
-
84857536692
-
Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer
-
Harbeck N, Rody A. Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer. J ClinOncol 2012, 30:686-689.
-
(2012)
J ClinOncol
, vol.30
, pp. 686-689
-
-
Harbeck, N.1
Rody, A.2
-
43
-
-
77954526150
-
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
-
10.1200/JCO.2009.25.6529, 2881855, 20404251
-
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Oncol 2010, 28:2784-2795. 10.1200/JCO.2009.25.6529, 2881855, 20404251.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2784-2795
-
-
Hammond, M.E.1
Hayes, D.F.2
Dowsett, M.3
Allred, D.C.4
Hagerty, K.L.5
Badve, S.6
Fitzgibbons, P.L.7
Francis, G.8
Goldstein, N.S.9
Hayes, M.10
Hicks, D.G.11
Lester, S.12
Love, R.13
Mangu, P.B.14
McShane, L.15
Miller, K.16
Osborne, C.K.17
Paik, S.18
Perlmutter, J.19
Rhodes, A.20
Sasano, H.21
Schwartz, J.N.22
Sweep, F.C.G.23
Taube, S.24
Torlakovic, E.E.25
Valenstein, P.26
Viale, G.27
Visscher, D.28
Wheeler, T.29
Williams, R.B.30
more..
-
44
-
-
41549123554
-
P27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer
-
Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, Castiglione-Gertsch M, Panzini I, Gianni L, Goldhirsch A, Coates A, Price KN, Gusterson BA, Viale G. p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Ann Oncol 2008, 19:660-668.
-
(2008)
Ann Oncol
, vol.19
, pp. 660-668
-
-
Ravaioli, A.1
Monti, F.2
Regan, M.M.3
Maffini, F.4
Mastropasqua, M.G.5
Spataro, V.6
Castiglione-Gertsch, M.7
Panzini, I.8
Gianni, L.9
Goldhirsch, A.10
Coates, A.11
Price, K.N.12
Gusterson, B.A.13
Viale, G.14
-
45
-
-
39149102890
-
Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
-
10.1093/jnci/djm289, 18230798, On the behalf of the International Breast Cancer Study G
-
Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovacs A, Pillay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS, . On the behalf of the International Breast Cancer Study G Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. J Natl Cancer Inst 2008, 100:207-212. 10.1093/jnci/djm289, 18230798, On the behalf of the International Breast Cancer Study G.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 207-212
-
-
Viale, G.1
Regan, M.M.2
Mastropasqua, M.G.3
Maffini, F.4
Maiorano, E.5
Colleoni, M.6
Price, K.N.7
Golouh, R.8
Perin, T.9
Brown, R.W.10
Kovacs, A.11
Pillay, K.12
Ohlschlegel, C.13
Gusterson, B.A.14
Castiglione-Gertsch, M.15
Gelber, R.D.16
Goldhirsch, A.17
Coates, A.S.18
-
46
-
-
0029759541
-
Annual hazard rates of recurrence for breast cancer after primary therapy
-
Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996, 14:2738-2746.
-
(1996)
J Clin Oncol
, vol.14
, pp. 2738-2746
-
-
Saphner, T.1
Tormey, D.C.2
Gray, R.3
-
47
-
-
66849140730
-
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
-
10.1093/jnci/djp082, 2684553, 19436038
-
Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. J Natl Cancer Inst 2009, 101:736-750. 10.1093/jnci/djp082, 2684553, 19436038.
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 736-750
-
-
Cheang, M.C.U.1
Chia, S.K.2
Voduc, D.3
Gao, D.4
Leung, S.5
Snider, J.6
Watson, M.7
Davies, S.8
Bernard, P.S.9
Parker, J.S.10
Perou, C.M.11
Ellis, M.J.12
Nielsen, T.O.13
-
48
-
-
38449108413
-
Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial
-
10.1093/jnci/djm287, 18182617, On behalf of the BIG
-
Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjold B, Lang I, Jakesz R, Vorobiof D, Gutierrez J, Van Hazel G, Dolci S, Jamin S, Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Piccart-Gebhart M, . On behalf of the BIG Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial. J Natl Cancer Inst 2008, 100:121-133. 10.1093/jnci/djm287, 18182617, On behalf of the BIG.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 121-133
-
-
Francis, P.1
Crown, J.2
Di Leo, A.3
Buyse, M.4
Balil, A.5
Andersson, M.6
Nordenskjold, B.7
Lang, I.8
Jakesz, R.9
Vorobiof, D.10
Gutierrez, J.11
Van Hazel, G.12
Dolci, S.13
Jamin, S.14
Bendahmane, B.15
Gelber, R.D.16
Goldhirsch, A.17
Castiglione-Gertsch, M.18
Piccart-Gebhart, M.19
-
49
-
-
77952848351
-
Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia
-
10.1158/0008-5472.CAN-09-3450, 2872114, 20466998
-
Diaz-Cruz ES, Furth PA. Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia. Cancer Res 2010, 70:3965-3974. 10.1158/0008-5472.CAN-09-3450, 2872114, 20466998.
-
(2010)
Cancer Res
, vol.70
, pp. 3965-3974
-
-
Diaz-Cruz, E.S.1
Furth, P.A.2
-
50
-
-
77956992175
-
Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation
-
10.1073/pnas.1009575107, 2930589, 20696891
-
Konduri SD, Medisetty R, Liu W, Kaipparettu BA, Srivastava P, Brauch H, Fritz P, Swetzig WM, Gardner AE, Khan SA, Das GM. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc Natl Acad Sci USA 2010, 107:15081-15086. 10.1073/pnas.1009575107, 2930589, 20696891.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 15081-15086
-
-
Konduri, S.D.1
Medisetty, R.2
Liu, W.3
Kaipparettu, B.A.4
Srivastava, P.5
Brauch, H.6
Fritz, P.7
Swetzig, W.M.8
Gardner, A.E.9
Khan, S.A.10
Das, G.M.11
-
51
-
-
67649832959
-
P53: structure, function and therapeutic applications
-
Bai L, Wei-Guo Z. p53: structure, function and therapeutic applications. Journal of Cancer Molecules 2006, 2:141-153.
-
(2006)
Journal of Cancer Molecules
, vol.2
, pp. 141-153
-
-
Bai, L.1
Wei-Guo, Z.2
-
52
-
-
84860390553
-
P53 mutant breast cancer patients expressing p53gamma have as good a prognosis as wild-type p53 breast cancer patients
-
10.1186/bcr2811, 3109573, 21251329
-
Bourdon JC, Khoury MP, Diot A, Baker L, Fernandes K, Aoubala M, Quinlan P, Purdie CA, Jordan LB, Prats AC, Lane DP, Thompson AM. p53 mutant breast cancer patients expressing p53gamma have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res 2011, 13:R7. 10.1186/bcr2811, 3109573, 21251329.
-
(2011)
Breast Cancer Res
, vol.13
-
-
Bourdon, J.C.1
Khoury, M.P.2
Diot, A.3
Baker, L.4
Fernandes, K.5
Aoubala, M.6
Quinlan, P.7
Purdie, C.A.8
Jordan, L.B.9
Prats, A.C.10
Lane, D.P.11
Thompson, A.M.12
-
53
-
-
84860339005
-
The p53 isoforms are differentially modified by Mdm2
-
Camus S, Menendez S, Fernandes K, Kua N, Liu G, Xirodimas DP, Lane DP, Bourdon JC. The p53 isoforms are differentially modified by Mdm2. Cell Cycle 2012, 11:1646-1655.
-
(2012)
Cell Cycle
, vol.11
, pp. 1646-1655
-
-
Camus, S.1
Menendez, S.2
Fernandes, K.3
Kua, N.4
Liu, G.5
Xirodimas, D.P.6
Lane, D.P.7
Bourdon, J.C.8
|